Foghorn Therapeutics Inc. operates as a clinical stage, precision therapeutics biotechnology company.
The company is pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting…
Analysis
Middle-of-the-road
Foghorn Therapeutics Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
Valuation data is not available for this company.
Growth is moderate; the safety picture is stretched. The company scores 7/20 on our value-creation score: creating some value. Analysts lean positive.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Mar 202674
76
2026
All-time high
76
Jun 2026
All-time low
74
Mar 2026
Average rank
75
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
72
—
—
—
Price/Earnings
37
—
—
—
Price/Book
74
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
59
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.